Dyne Therapeutics Q3 net loss widens on higher trial costs

Overview

• U.S. neuromuscular disease biotech's Q3 net loss widened and missed analyst expectations

• Q3 operating loss increased and missed analyst expectations

• Higher R&D and G&A expenses driven by manufacturing and clinical trial costs, plus launch preparations

Outlook

• Company expects potential U.S. launch of z-rostudirsen in Q1 2027, pending FDA approval

• Topline data from ACHIEVE REC for z-basivarsen expected in Q1 2027

• Company expects potential U.S. launch of z-basivarsen in H1 2028, pending regulatory approval

Result Drivers

• MANUFACTURING AND CLINICAL TRIAL COSTS - Co said higher R&D expenses were mainly due to increased manufacturing for z-rostudirsen and clinical trial costs for FORZETTO and HARMONIA Phase 3 trials

• LAUNCH PREPARATIONS - Co attributed higher G&A expenses to preparations for potential launch of z-rostudirsen, including increased headcount

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Dyne Therapeutics, Inc. is $36.50, about 96.9% above its November 4 closing price of $18.54

Reuters Recommended Reads

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)